IOL Chemicals and Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹2,319cr+11.5% on FY25
EBITDA: ₹269cr+33.0% on FY25
Net profit: ₹138cr+36.2% on FY25
EPS: ₹4.69+36.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,524	2,319	2,079	2,133	2,217	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	22.2	21.4	22.4	30.1	25.6
	2,546	2,340	2,102	2,163	2,243
	1,632	1,502	1,358	1,435	1,536
	4.8	4.0	0.0	0.2	29.2
	−35.7	−18.5	33.5	−38.3	−18.2
	262	248	217	201	168
	14.0	14.6	14.8	16.1	16.5
	81.8	80.2	72.0	62.9	46.2
	351	315	268	304	276
	2,309	2,145	1,964	1,981	2,054
	310	269	202	231	226
	229	189	130	168	180
Profit
	237	196	138	182	189
	−11.2	−11.2	0.0	0.0	0.0
	226	184	138	182	189
	51.8	40.6	24.7	37.0	46.3
	5.6	6.2	12.2	10.2	3.3
	57.4	46.7	36.9	47.2	49.5
	168	138	101	134	139
	168	138	101	134	139
	2.2	2.6	−1.4	−1.3	−0.2
	170	140	99.6	133	139
Per share
	₹5.73	₹4.69	₹3.44	₹22.90	₹23.70
	₹5.73	₹4.69	₹3.44	₹22.90	₹23.70
Other comprehensive income — detail
	2.2	2.6	−1.4	—	—
	3.1	2.6	−1.0	−1.7	−0.5
	0.8	0.7	−0.2	—	—
	—	—	—	−0.4	−0.1
	−0.2	0.9	−1.0	—	0.2
	−0.0	0.2	−0.2	—	—
	—	—	—	0.0	0.1
Per share — as-filed variants
	₹5.73	₹4.69	₹3.44	₹22.90	₹23.70
	₹5.73	₹4.69	₹3.44	₹22.90	₹23.70
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	923	832	687	736	670
	36.6%	35.9%	33.1%	34.5%	30.2%
Adjusted (ex-exceptional items) — derived
	237	196	138	182	189
	−11.2	−11.2	0.0	0.0	0.0
	176	146	101	134	139
	₹6.01	₹4.98	₹3.44	₹22.90	₹23.70

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IOLCP₹180.62

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMOREPENLAB FDC INNOVACAP ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹5,302 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,217.1	2,132.8	2,079.2	2,319.1	2,523.6
Other Income	25.6	30.1	22.4	21.4	22.2
Total Income	2,242.7	2,162.9	2,101.6	2,340.4	2,545.8
Expenses
+ Cost of Materials Consumed	1,536.1	1,435.1	1,358.3	1,501.6	1,631.8
+ Purchases of Stock-in-Trade	29.2	0.2	0.0	4.0	4.8
+ Changes in Inventories	-18.2	-38.3	33.5	-18.5	-35.7
+ Employee Benefit Expense	168.2	201.0	216.6	248.3	261.8
+ Finance Costs	16.5	16.1	14.8	14.6	14.0
+ Depreciation & Amortisation	46.2	62.9	72.0	80.2	81.8
+ Other Expenses	276.1	304.2	268.5	314.7	350.6
Total Expenses	2,054.1	1,981.2	1,963.7	2,144.9	2,309.1
EBITDA	225.7	230.6	202.3	269.0	310.3
EBIT	179.5	167.7	130.3	188.7	228.5
Profit
PBT before Exceptional Items	188.7	181.7	138.0	195.6	236.8
+ Exceptional Items	0.0	0.0	0.0	-11.2	-11.2
Pretax Income	188.7	181.7	138.0	184.4	225.5
+ Current Tax	46.3	37.0	24.7	40.6	51.8
+ Deferred Tax	3.3	10.2	12.2	6.2	5.6
Tax Expense	49.5	47.2	36.9	46.7	57.4
Net Income	139.1	134.4	101.1	137.6	168.1
+ Net Income — Continuing Ops	139.1	134.4	101.1	137.6	168.1
+ Other Comprehensive Income	-0.2	-1.3	-1.4	2.6	2.2
Total Comprehensive Income	138.9	133.1	99.6	140.2	170.3
Per Share
Basic EPS	23.70	22.90	3.44	4.69	5.73
Diluted EPS	23.70	22.90	3.44	4.69	5.73
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-1.4	2.6	2.2
+ Items NOT to be Reclassified to P&L	-0.5	-1.7	-1.0	2.6	3.1
+ Tax on Items NOT to be Reclassified	—	—	-0.2	0.7	0.8
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.4	—	—	—
+ Items to be Reclassified to P&L	0.2	—	-1.0	0.9	-0.2
+ Tax on Items to be Reclassified	—	—	-0.2	0.2	-0.0
+ Tax on Items to be Reclassified — alt tag	0.1	0.0	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	23.70	22.90	3.44	4.69	5.73
Diluted EPS — Continuing Operations	23.70	22.90	3.44	4.69	5.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	670.0	735.8	687.4	832.0	922.8
Gross Margin %	30.22	34.50	33.06	35.87	36.57
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	188.7	181.7	138.0	195.6	236.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-11.2	-11.2
Net Income Adj (tax-effected)	139.1	134.4	101.1	146.0	176.5
EPS Adj	23.70	22.90	3.44	4.98	6.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	2.00	2.00	2.00
Paid Up Equity Capital	58.7	58.7	58.7	58.7	58.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.